***Pharmaceutical Benefits Advisory Committee***

Email: PBAC@health.gov.au Address all mail to:

PBAC Secretariat

GPO Box 9848

Canberra ACT 2601

**DELISTING OF PHARMACEUTICAL BENEFIT ITEMS**

**EFFECTIVE 01 JUNE 2024**

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act* *1953*, with effect from the above date.

|  |  |
| --- | --- |
| **Item** | **PBAC Advice** |
| Ketoconazole | The sponsor requested the delisting of Nizoral® 2% cream (ketoconazole) from the Pharmaceutical Benefits Scheme (PBS).  The Pharmaceutical Benefits Advisory Committee (PBAC) noted the sponsor’s plans to discontinue manufacture of Nizoral 2% cream and that there are alternative products available on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need. |



Vanessa McMahon

Director, PBAC Assessment Section

Office of Health Technology Assessment

Technology Assessment and Access Division

16 May 2024